Microdosing vs. Macrodosing

The distinction between microdosing and macrodosing is not just about quantity — it’s about intention, experience, risk profile, and evidence base. Understanding the difference is essential for anyone considering psychedelics for mental health.

What Is a Macrodose?

A macrodose is a full, perceptible dose of a psychedelic — enough to produce significant alterations in consciousness, perception, and cognition. This is the dose range used in virtually all clinical trials of psychedelic-assisted therapy.

For psilocybin, a typical therapeutic macrodose is 20–30 mg of psilocybin (roughly 3–5 grams of dried Psilocybe cubensis mushrooms, though potency varies enormously by species and batch). For LSD, a full dose is typically 75–200 micrograms.

A macrodose experience typically lasts 6–8 hours for psilocybin and 8–12 hours for LSD. It is internally intense, often emotionally vivid, and generally requires a full day set aside plus a day or two after for integration.

What Is Microdosing?

Microdosing involves taking a sub-perceptual dose — typically about 1/10th to 1/20th of a recreational dose — on a regular schedule. The goal is not to trip but to purportedly enhance mood, creativity, focus, or emotional flexibility.

Common microdose ranges:

• Psilocybin: 0.05–0.3 grams dried mushrooms
• LSD: 5–20 micrograms

A true microdose should be subtle to imperceptible. If you’re clearly feeling altered, it’s not a microdose.

Common Microdosing Protocols

The Fadiman Protocol

Named by and associated with Dr. James Fadiman, this is the most well-known schedule: one day on, two days off. The theory is that the effects may persist into the off days, and this schedule reduces tolerance buildup.

The Stamets Protocol

Popularized by mycologist Paul Stamets, this involves dosing for four consecutive days followed by three days off. Stamets has also suggested combining psilocybin with lion’s mane mushroom and niacin, though the evidence for this specific stack is anecdotal.

Intuitive Protocol

Some people dose simply when they feel they need it, without a fixed schedule. This requires honest self-assessment and carries a higher risk of unconscious escalation.

What the Research Actually Shows

Macrodosing

The evidence for macrodose psychedelic therapy is the strongest in the field. Key findings include:

• Johns Hopkins (Davis et al., 2021): Two doses of psilocybin plus therapy produced rapid, large reductions in depression scores. Four times as many participants in the psilocybin group met remission criteria compared to the placebo group at week 4.
• Imperial College London (Carhart-Harris et al., 2021): Psilocybin was at least as effective as escitalopram (Lexapro) for depression in a head-to-head trial.
• MAPS (now Lykos) MDMA trials: Phase 3 trials for PTSD showed that 67% of participants in the MDMA group no longer met PTSD criteria after three sessions, compared to 32% in the placebo group. Note: The FDA declined to approve MDMA-assisted therapy in August 2024, requesting additional data. The science is promising but not settled.

These trials all involve structured preparation, supervised sessions, and integration therapy. They are not simply “take a pill and feel better.”

Microdosing

The microdosing evidence base is far weaker and more mixed:

• Hutten et al. (2020) / Nature: A naturalistic study found microdosers reported better mental health and focus than non-microdosers, but this was not placebo-controlled.
• Polito & Stevenson (2019): Found subtle subjective effects on dose days but no clear cumulative benefits.
• Multiple placebo-controlled studies (2021–2023): Several rigorous lab studies using blinding have found that the benefits people report from microdosing are largely indistinguishable from placebo. Participants do report benefits — but so do people taking inactive substances who believe they took psychedelics.

The bottom line: Microdosing may help some people, but the evidence does not currently support the magnitude of claims commonly made online. The placebo effect is powerful and real — if you feel better, you feel better — but we should be honest about why.

Realistic Expectations

For Macrodosing

• Not every experience is healing. Some are difficult, confusing, or emotionally painful.
• Benefits, when they occur, often require active integration work afterward.
• A single session is rarely a “cure.” Most clinical protocols involve 2–3 sessions.
• Set and setting matter enormously. A chaotic environment or resistant mindset reduces benefits and increases risk.

For Microdosing

• Effects are subtle. If you’re looking for dramatic change, microdosing is unlikely to deliver.
• The science suggests much of the benefit may be placebo-driven. This isn’t nothing — placebo effects are genuine neurobiological events — but it’s different from a pharmacological cure.
• Tolerance builds quickly with frequent dosing, which is why protocols include off days.
• Long-term safety data is essentially nonexistent.

Key Risks Compared

Risk Factor	Macrodose	Microdose
Serotonin syndrome (with SSRIs/MAOIs)	Higher acute risk	Lower but not zero
Cardiovascular (especially 5-HT2B agonism)	Single exposure lower	Chronic exposure unknown, theoretically concerning
Psychological distress	High during experience	Lower, but mood instability possible
Psychosis trigger	Significant risk with history	Probably lower but not absent
Legal risk	High	High
Tolerance/dependence	Low per session	Moderate risk with frequent use

Which Is Right for You?

We can’t answer that, and we won’t try. But we can offer an honest framing:

• If you are seeking substantial psychological shift and are prepared for an intense experience, the evidence base for macrodose therapy is stronger — but so are the risks and requirements.
• If you are curious but cautious, or unable to commit the time and support a macrodose requires, microdosing is lower-intensity — but the evidence for specific benefits is weaker.
• If you are on SSRIs, SNRIs, MAOIs, lithium, or have a personal or family history of psychosis or bipolar disorder, neither may be safe for you. See Harm Reduction Essentials and When NOT to Trip.

Sources & Further Reading

• Davis et al. (2021), JAMA Psychiatry — Psilocybin for depression
• Carhartt-Harris et al. (2021), NEJM — Psilocybin vs. escitalopram
• Mitchell et al. (2021), Nature Medicine — MDMA-assisted therapy for PTSD
• Hutten et al. (2020), Nature — Microdosing survey
• Fadiman, J. — The Psychedelic Explorer’s Guide